IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?

iShares U.S. Pharmaceuticals ETF (IHE) is the lower-cost and higher-yield option versus Invesco Pharmaceuticals ETF (PJP), charging 0.38% vs 0.57% and paying a 1.62% dividend vs 0.96%. IHE’s concentrated structure (top two holdings ~44%: Eli Lilly 24.2% and Johnson & Johnson 20.3%) has helped deliver stronger 5-year growth of $1,747 vs PJP’s $1,562 and a slightly shallower 5-year max drawdown (-16.02% vs -17.51%). PJP’s more even top-heavy allocation (top holding weights ~5% each) may reduce single-name risk, but the article suggests IHE has performed better over the period due to its tilt toward Lilly’s strength.

Analysis

This is less a choice between two ETFs than a choice between two factor exposures. IHE is effectively a concentrated bet on whether LLY can keep compounding and whether JNJ stays a low-volatility anchor; PJP is the cleaner way to own the group without letting one or two mega-cap names dominate the outcome. That matters because in pharma, concentration amplifies both price discovery and drawdown risk around a single trial readout, pricing headline, or legal update.

Near term, momentum can keep favoring IHE because markets usually reward quality compounders and balance-sheet strength before they reward diversification. The reversal risk is not an industry-wide collapse; it is a single-name de-rating in LLY or a renewed JNJ overhang, either of which would hit IHE disproportionately within days to weeks. Over 1-3 months, PJP becomes more attractive if investors rotate toward broader healthcare breadth or if mega-cap pharma loses leadership to lower-quality but higher-upside names.

The contrarian miss is that fee and yield are not the real decision variables here; concentration is. IHE is the better vehicle only if the investor explicitly wants embedded LLY exposure, while PJP is superior if the goal is sector beta with less hidden single-name risk. In 6-18 months, if the market broadens beyond a narrow group of winners, PJP should hold up better on a risk-adjusted basis even if it lags in a continued mega-cap melt-up.

Key Decisions for Investors

• Relative-value: go long PJP / short IHE for 1-3 months if you expect LLY or JNJ event risk to rise; thesis works if the mega-cap pharma leadership narrows and IHE/PJP spread mean-reverts. Falsify if LLY keeps outperforming and no negative catalyst emerges.
• Use IHE only as an expression of constructive LLY/JNJ views; if the intent is diversified pharma beta, prefer PJP. This avoids accidentally doubling up on a near-single-name exposure disguised as a sector ETF.
• If you already own LLY, avoid adding IHE on top unless you want to explicitly lever that view through the ETF wrapper. PJP is the better hedge against a sudden LLY multiple reset or JNJ-specific headline risk over the next quarter.
• Set a watch item on LLY guidance and any JNJ litigation/regulatory update; those are the primary falsifiers for the IHE-outperformance narrative. If neither materializes, the pair trade should be covered rather than forced.